Among cases, however, significantly higher levels of two specific anti-TAA (PGM3 and TTN) were observed in ANA-positive compared to ANA-negative women (Table 2), and in covariate-adjusted models, significantly higher anti-TTN levels were seen in women diagnosed with breast cancer within seven years (Table 4). This evidence concerns the gene BTG3 and breast cancer.